{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:49Z","timestamp":1792784929126,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:00:00Z","timestamp":1791676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:00:00Z","timestamp":1791676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Swedish Ministry for Foreign Affairs","award":["UD2022\/000123"],"award-info":[{"award-number":["UD2022\/000123"]}],"id":[{"id":"https:\/\/ror.org\/01251sa74","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Swedish Ministry for Foreign Affairs","award":["UD2022\/000123"],"award-info":[{"award-number":["UD2022\/000123"]}],"id":[{"id":"https:\/\/ror.org\/01251sa74","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Swedish Ministry for Foreign Affairs","award":["UD2022\/000123"],"award-info":[{"award-number":["UD2022\/000123"]}],"id":[{"id":"https:\/\/ror.org\/01251sa74","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01607-5","type":"journal-article","created":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T07:45:27Z","timestamp":1791704727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A staged clinical development and evidence-generation framework for Group A Streptococcus vaccines"],"prefix":"10.1038","volume":"11","author":[{"given":"Alberto","family":"Cagigi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Anh","family":"Wartel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Steer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1182-9792","authenticated-orcid":false,"given":"Jonathan","family":"Carapetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Fulurija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0461-6438","authenticated-orcid":false,"given":"Jerome H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,11]]},"reference":[{"key":"1607_CR1","doi-asserted-by":"publisher","first-page":"6968","DOI":"10.1016\/j.vaccine.2018.10.001","volume":"36","author":"JW Cannon","year":"2018","unstructured":"Cannon, J. W. et al. An economic case for a vaccine to prevent group A streptococcus skin infections. Vaccine 36, 6968\u20136978 https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.001 (2018).","journal-title":"Vaccine"},{"key":"1607_CR2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1056\/NEJMoa1603693","volume":"377","author":"DA Watkins","year":"2017","unstructured":"Watkins, D. A. et al. Global, regional, and national burden of rheumatic heart disease, 1990-2015.  N. Engl. J. Med. 377, 713\u2013722 https:\/\/doi.org\/10.1056\/NEJMoa1603693 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1607_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/s1473-3099(05)70267-x","volume":"5","author":"JR Carapetis","year":"2005","unstructured":"Carapetis, J. R., Steer, A. C., Mulholland, E. K. & Weber, M. The global burden of group A streptococcal diseases.  Lancet Infect. Dis. 5, 685\u2013694 https:\/\/doi.org\/10.1016\/s1473-3099(05)70267-x (2005).","journal-title":"Lancet Infect. Dis."},{"key":"1607_CR4","doi-asserted-by":"crossref","unstructured":"Hand, R. M., Snelling, T. L. & Carapetis, J. R. in Hunter\u2019s Tropical Medicine and Emerging Infectious Diseases (Tenth Edition) (eds Ryan, E. T. et al.) 429-438 (Elsevier, 2020).","DOI":"10.1016\/B978-0-323-55512-8.00040-5"},{"key":"1607_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ijid.2020.11.193","volume":"103","author":"JW Cannon","year":"2021","unstructured":"Cannon, J. W. et al. The economic and health burdens of diseases caused by group A Streptococcus in New Zealand. Int J. Infect. Dis. 103, 176\u2013181 https:\/\/doi.org\/10.1016\/j.ijid.2020.11.193 (2021).","journal-title":"Int J. Infect. Dis."},{"key":"1607_CR6","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/cid\/ciy1143","volume":"69","author":"J Vekemans","year":"2019","unstructured":"Vekemans, J. et al. The path to group A Streptococcus vaccines: World Health Organization research and development technology roadmap and preferred product characteristics. Clin. Infect. Dis. 69, 877\u2013883 https:\/\/doi.org\/10.1093\/cid\/ciy1143 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"1607_CR7","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1093\/cid\/ciac291","volume":"75","author":"HC Moore","year":"2022","unstructured":"Moore, H. C. et al. A systematic framework for prioritizing burden of disease data required for vaccine development and implementation: the case for group A Streptococcal diseases. Clin. Infect. Dis. 75, 1245\u20131254 https:\/\/doi.org\/10.1093\/cid\/ciac291 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"1607_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00609-x","volume":"8","author":"DR Walkinshaw","year":"2023","unstructured":"Walkinshaw, D. R. et al. The Streptococcus pyogenes vaccine landscape. NPJ Vaccines 8, 16 https:\/\/doi.org\/10.1038\/s41541-023-00609-x (2023).","journal-title":"NPJ Vaccines"},{"key":"1607_CR9","unstructured":"Coefficient Giving. Announcing the Strep A Vaccine Fund, https:\/\/coefficientgiving.org\/research\/announcing-the-strep-a-vaccine-fund\/ (2026)."},{"key":"1607_CR10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/QCO.0000000000000644","volume":"33","author":"JB Dale","year":"2020","unstructured":"Dale, J. B. & Walker, M. J. Update on group A streptococcal vaccine development. Curr. Opin. Infect. Dis. 33, 244\u2013250 https:\/\/doi.org\/10.1097\/QCO.0000000000000644 (2020).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"1607_CR11","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41588-019-0417-8","volume":"51","author":"MR Davies","year":"2019","unstructured":"Davies, M. R. et al. Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics. Nat. Genet. 51, 1035\u20131043 https:\/\/doi.org\/10.1038\/s41588-019-0417-8 (2019).","journal-title":"Nat. Genet."},{"key":"1607_CR12","doi-asserted-by":"publisher","unstructured":"Belete, M. A., Toth, I., Stephenson, R. & Skwarczynski, M. Rational selection of antigenic targets for Group A Streptococcus vaccine: updates, challenges and opportunities. NPJ Vaccines 11 https:\/\/doi.org\/10.1038\/s41541-026-01445-5 (2026).","DOI":"10.1038\/s41541-026-01445-5"},{"key":"1607_CR13","doi-asserted-by":"publisher","first-page":"8175","DOI":"10.1016\/j.vaccine.2011.09.005","volume":"29","author":"JB Dale","year":"2011","unstructured":"Dale, J. B., Penfound, T. A., Chiang, E. Y. & Walton, W. J. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine 29, 8175\u20138178 https:\/\/doi.org\/10.1016\/j.vaccine.2011.09.005 (2011).","journal-title":"Vaccine"},{"key":"1607_CR14","doi-asserted-by":"publisher","first-page":"8250","DOI":"10.1016\/J.VACCINE.2011.08.113","volume":"29","author":"MT Guerino","year":"2011","unstructured":"Guerino, M. T. et al. HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate. Vaccine 29, 8250\u20138256 https:\/\/doi.org\/10.1016\/J.VACCINE.2011.08.113 (2011).","journal-title":"Vaccine"},{"key":"1607_CR15","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.4049\/jimmunol.1700836","volume":"199","author":"T Nordstr\u00f6m","year":"2017","unstructured":"Nordstr\u00f6m, T. et al. Enhancing vaccine efficacy by engineering a complex synthetic peptide to become a super immunogen. J. Immunol. 199, 2794 https:\/\/doi.org\/10.4049\/jimmunol.1700836 (2017).","journal-title":"J. Immunol."},{"key":"1607_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/MBIO.03537-20\/SUPPL_FILE\/MBIO.03537-20-ST001.PDF","volume":"12","author":"V Ozberk","year":"2021","unstructured":"Ozberk, V. et al. Prime-pull immunization with a bivalent m-protein and spy-cep peptide vaccine adjuvanted with caf\u00ae01 liposomes induces both mucosal and peripheral protection from covr\/s mutant streptococcus pyogenes. mBio 12, 1\u201315 https:\/\/doi.org\/10.1128\/MBIO.03537-20\/SUPPL_FILE\/MBIO.03537-20-ST001.PDF (2021).","journal-title":"mBio"},{"key":"1607_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-14157-7","volume":"7","author":"M Pandey","year":"2017","unstructured":"Pandey, M. et al. Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase i trial. Sci. Rep. 7, 1\u201311 https:\/\/doi.org\/10.1038\/s41598-017-14157-7 (2017).","journal-title":"Sci. Rep."},{"key":"1607_CR18","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.vaccine.2019.12.005","volume":"38","author":"E Pastural","year":"2020","unstructured":"Pastural, E. et al. Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: a randomized, controlled phase I study. Vaccine 38, 1384\u20131392 https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.005 (2020).","journal-title":"Vaccine"},{"key":"1607_CR19","doi-asserted-by":"publisher","first-page":"e60969","DOI":"10.1371\/JOURNAL.PONE.0060969","volume":"8","author":"E Postol","year":"2013","unstructured":"Postol, E. et al. StreptInCor: a candidate vaccine epitope against S. pyogenes infections induces protection in outbred mice. PLoS ONE 8, e60969\u2013e60969 https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0060969 (2013).","journal-title":"PLoS ONE"},{"key":"1607_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-46244-2","volume":"9","author":"E Postol","year":"2019","unstructured":"Postol, E. et al. Group A Streptococcus adsorbed vaccine: repeated intramuscular dose toxicity test in minipigs. Sci. Rep. 9, 1\u201312 https:\/\/doi.org\/10.1038\/s41598-019-46244-2 (2019).","journal-title":"Sci. Rep."},{"key":"1607_CR21","doi-asserted-by":"publisher","unstructured":"S\u00e1-Rocha, L. C. d. StreptInCor, a Group A Streptococcal adsorbed vaccine: evaluation of repeated intramuscular dose toxicity testing in rats. Front. Cardiovasc. Med. 8, 643317\u2013643317 https:\/\/doi.org\/10.3389\/FCVM.2021.643317 (2021).","DOI":"10.3389\/FCVM.2021.643317"},{"key":"1607_CR22","doi-asserted-by":"publisher","unstructured":"Salie, T. et al. Systematic review and meta-analysis of the prevalence of group A Streptococcal emm clusters in Africa to inform vaccine development. mSphere 5 https:\/\/doi.org\/10.1128\/mSphere.00429-20 (2020).","DOI":"10.1128\/mSphere.00429-20"},{"key":"1607_CR23","doi-asserted-by":"publisher","first-page":"e0198658","DOI":"10.1371\/journal.pone.0198658","volume":"13","author":"S Sekuloski","year":"2018","unstructured":"Sekuloski, S. et al. Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial. PLoS ONE 13, e0198658 https:\/\/doi.org\/10.1371\/journal.pone.0198658 (2018).","journal-title":"PLoS ONE"},{"key":"1607_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/srep39274","volume":"6","author":"M Zaman","year":"2016","unstructured":"Zaman, M. et al. Novel platform technology for modular mucosal vaccine that protects against streptococcus. Sci. Rep. 6, 39274 https:\/\/doi.org\/10.1038\/srep39274 (2016).","journal-title":"Sci. Rep."},{"key":"1607_CR25","doi-asserted-by":"publisher","unstructured":"Castro, S. A. & Dorfmueller, H. C. A brief review on Group A Streptococcus pathogenesis and vaccine development. R. Soc. Open Sci. 8 https:\/\/doi.org\/10.1098\/RSOS.201991 (2021).","DOI":"10.1098\/RSOS.201991"},{"key":"1607_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80508-6","volume":"11","author":"S Reynolds","year":"2021","unstructured":"Reynolds, S. et al. Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines. Sci. Rep. 11, 127 https:\/\/doi.org\/10.1038\/s41598-020-80508-6 (2021).","journal-title":"Sci. Rep."},{"key":"1607_CR27","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1208\/s12248-017-0069-5","volume":"19","author":"E Burlet","year":"2017","unstructured":"Burlet, E., HogenEsch, H., Dunham, A. & Morefield, G. Evaluation of the potency, neutralizing antibody response, and stability of a recombinant fusion protein vaccine for Streptococcus pyogenes. AAPS J. 19, 875\u2013881 https:\/\/doi.org\/10.1208\/s12248-017-0069-5 (2017).","journal-title":"AAPS J."},{"key":"1607_CR28","doi-asserted-by":"publisher","unstructured":"Castro A. S. et al. Recombinant production platform for Group A Streptococcus glycoconjugate vaccines. NPJ Vaccines. 10, 16. https:\/\/doi.org\/10.1038\/s41541-025-01068-2 (2025).","DOI":"10.1038\/s41541-025-01068-2"},{"key":"1607_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1074\/mcp.M111.015693","volume":"11","author":"G Bensi","year":"2012","unstructured":"Bensi, G. et al. Multi high-throughput approach for highly selective identification of vaccine candidates: The group a streptococcus case. Mol. Cell. Proteom. 11, 1\u201312 https:\/\/doi.org\/10.1074\/mcp.M111.015693 (2012).","journal-title":"Mol. Cell. Proteom."},{"key":"1607_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1128\/IAI.00916-13","volume":"82","author":"ZT Cusumano","year":"2014","unstructured":"Cusumano, Z. T., Watson, M. E. Jr. & Caparon, M. G. Streptococcus pyogenes arginine and citrulline catabolism promotes infection and modulates innate immunity. Infect. Immun. 82, 233\u2013242 https:\/\/doi.org\/10.1128\/IAI.00916-13 (2014).","journal-title":"Infect. Immun."},{"key":"1607_CR31","doi-asserted-by":"publisher","unstructured":"Pitirollo, O. et al. Elucidating the role of N-acetylglucosamine in Group A Carbohydrate for the development of an effective glycoconjugate vaccine against Group A Streptococcus. Carbohydr Polym. 311, 120736 https:\/\/doi.org\/10.1016\/j.carbpol.2023.120736 (2023).","DOI":"10.1016\/j.carbpol.2023.120736"},{"key":"1607_CR32","doi-asserted-by":"publisher","unstructured":"Di Benedetto, R. et al. Rational design of a glycoconjugate vaccine against group A Streptococcus. Int. J. Mol. Sci. 21 https:\/\/doi.org\/10.3390\/ijms21228558 (2020).","DOI":"10.3390\/ijms21228558"},{"key":"1607_CR33","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1086\/432485","volume":"192","author":"RJ Edwards","year":"2005","unstructured":"Edwards, R. J. et al. Specific C-terminal cleavage and inactivation of interleukin-8 by invasive disease isolates of Streptococcus pyogenes. J. Infect. Dis. 192, 783\u2013790 https:\/\/doi.org\/10.1086\/432485 (2005).","journal-title":"J. Infect. Dis."},{"key":"1607_CR34","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1128\/IAI.00064-14","volume":"82","author":"M Gallotta","year":"2014","unstructured":"Gallotta, M. et al. SpyAD, a moonlighting protein of group A Streptococcus contributing to bacterial division and host cell adhesion. Infect. Immun. 82, 2890\u20132901 https:\/\/doi.org\/10.1128\/IAI.00064-14 (2014).","journal-title":"Infect. Immun."},{"key":"1607_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/IM9.0000000000000044","volume":"3","author":"NJ Gao","year":"2021","unstructured":"Gao, N. J. et al. Site-specific conjugation of cell wall polyrhamnose to protein SpyAD envisioning a safe universal group A Streptococcal vaccine. Infect. Microbes Dis. 3, 87\u2013100 https:\/\/doi.org\/10.1097\/IM9.0000000000000044 (2021).","journal-title":"Infect. Microbes Dis."},{"key":"1607_CR36","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/J.VACCINE.2010.09.018","volume":"29","author":"A Kabanova","year":"2010","unstructured":"Kabanova, A. et al. Evaluation of a Group A Streptococcus synthetic oligosaccharide as vaccine candidate. Vaccine 29, 104\u2013114 https:\/\/doi.org\/10.1016\/J.VACCINE.2010.09.018 (2010).","journal-title":"Vaccine"},{"key":"1607_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-83673-4","volume":"11","author":"JMS Loh","year":"2021","unstructured":"Loh, J. M. S. et al. A multivalent T-antigen-based vaccine for Group A Streptococcus. Sci. Rep. 11, 1\u201310 https:\/\/doi.org\/10.1038\/s41598-021-83673-4 (2021).","journal-title":"Sci. Rep."},{"key":"1607_CR38","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1128\/JB.185.12.3661-3667.2003","volume":"185","author":"WR Lyon","year":"2003","unstructured":"Lyon, W. R. & Caparon, M. G. Trigger factor-mediated prolyl isomerization influences maturation of the Streptococcus pyogenes cysteine protease. J. Bacteriol. 185, 3661\u20133667 https:\/\/doi.org\/10.1128\/JB.185.12.3661-3667.2003 (2003).","journal-title":"J. Bacteriol."},{"key":"1607_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.00693-19","volume":"10","author":"T Rivera-Hernandez","year":"2019","unstructured":"Rivera-Hernandez, T. et al. An experimental group a streptococcus vaccine that reduces pharyngitis and tonsillitis in a nonhuman primate model. mBio 10, 1\u201310 https:\/\/doi.org\/10.1128\/mBio.00693-19 (2019).","journal-title":"mBio"},{"key":"1607_CR40","doi-asserted-by":"publisher","first-page":"e00618","DOI":"10.1128\/mBio.00618-16","volume":"7","author":"T Rivera-Hernandez","year":"2016","unstructured":"Rivera-Hernandez, T. et al. Differing efficacies of lead group A streptococcal vaccine candidates and full-length M protein in cutaneous and invasive disease models. mBio 7, e00618\u201300616 https:\/\/doi.org\/10.1128\/mBio.00618-16 (2016).","journal-title":"mBio"},{"key":"1607_CR41","doi-asserted-by":"crossref","unstructured":"Rivera-Hernandez, T. et al. Vaccine-induced Th1-type response protects against invasive group A Streptococcus infection in the absence of opsonizing antibodies. mBio 11, e00122-20 (2020).","DOI":"10.1128\/mBio.00122-20"},{"key":"1607_CR42","unstructured":"Vaxcyte. Corporate Presentation, https:\/\/investors.vaxcyte.com (2022)."},{"key":"1607_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01272-0","volume":"10","author":"T Parks","year":"2025","unstructured":"Parks, T., Cunningham, M. W. & Saul, A. No compelling evidence that vaccination with streptococcus pyogenes group A carbohydrate elicits cross-reactive rheumatic fever autoantibodies. NPJ Vaccines 10, 224 https:\/\/doi.org\/10.1038\/s41541-025-01272-0 (2025).","journal-title":"NPJ Vaccines"},{"key":"1607_CR44","doi-asserted-by":"publisher","unstructured":"Frost, H., Excler, J. L., Sriskandan, S. & Fulurija, A. Correlates of immunity to Group A Streptococcus: a pathway to vaccine development. NPJ Vaccines 8, https:\/\/doi.org\/10.1038\/s41541-022-00593-8 (2023).","DOI":"10.1038\/s41541-022-00593-8"},{"key":"1607_CR45","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1001\/jama.1969.03150190037007","volume":"207","author":"BF Massell","year":"1969","unstructured":"Massell, B. F., Honikman, L. H. & Amezcua, J. Rheumatic fever following streptococcal vaccination. Report of three cases. JAMA 207, 1115\u20131119 (1969).","journal-title":"JAMA"},{"key":"1607_CR46","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/trstmh\/trz014","volume":"113","author":"CK Macleod","year":"2019","unstructured":"Macleod, C. K. et al. Neglecting the neglected: the objective evidence of underfunding in rheumatic heart disease. Trans. R. Soc. Trop. Med Hyg. 113, 287\u2013290 https:\/\/doi.org\/10.1093\/trstmh\/trz014 (2019).","journal-title":"Trans. R. Soc. Trop. Med Hyg."},{"key":"1607_CR47","unstructured":"Organization, W. H. WHO guideline on the prevention and diagnosis of rheumatic fever and rheumatic heart disease, https:\/\/www.who.int\/publications\/i\/item\/9789240100077 (2024)."},{"key":"1607_CR48","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1001\/jama.2016.4151","volume":"315","author":"KE Fleming-Dutra","year":"2016","unstructured":"Fleming-Dutra, K. E. et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. JAMA 315, 1864\u20131873 https:\/\/doi.org\/10.1001\/jama.2016.4151 (2016).","journal-title":"JAMA"},{"key":"1607_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101458","volume":"48","author":"KM Miller","year":"2022","unstructured":"Miller, K. M. et al. The global burden of sore throat and group A Streptococcus pharyngitis: a systematic review and meta-analysis. EClinicalMedicine 48, 101458. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101458 (2022).","journal-title":"EClinicalMedicine"},{"key":"1607_CR50","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5334\/gh.1564","volume":"21","author":"SH Wirth","year":"2026","unstructured":"Wirth, S. H., Beaton, A. Z. & Steer, A. Streptococcus pyogenes and acute rheumatic fever: how strong are the links in the chain? Glob. Heart 21, 48 https:\/\/doi.org\/10.5334\/gh.1564 (2026).","journal-title":"Glob. Heart"},{"key":"1607_CR51","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1016\/S2666-5247(20)30240-8","volume":"2","author":"J Osowicki","year":"2021","unstructured":"Osowicki, J. et al. A controlled human infection model of Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study. Lancet Microbe 2, e291\u2013e299 https:\/\/doi.org\/10.1016\/S2666-5247(20)30240-8 (2021).","journal-title":"Lancet Microbe"},{"key":"1607_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2026.134432","volume":"453","author":"J Marangou","year":"2026","unstructured":"Marangou, J. et al. Early rheumatic heart disease is a recognized intermediate on the pathway to advanced rheumatic heart disease. Int. J. Cardiol. 453, 134432 https:\/\/doi.org\/10.1016\/j.ijcard.2026.134432 (2026).","journal-title":"Int. J. Cardiol."},{"key":"1607_CR53","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41569-023-00940-9","volume":"21","author":"J Rwebembera","year":"2024","unstructured":"Rwebembera, J. et al. 2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease. Nat. Rev. Cardiol. 21, 250\u2013263 https:\/\/doi.org\/10.1038\/s41569-023-00940-9 (2024).","journal-title":"Nat. Rev. Cardiol."},{"key":"1607_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-025-05484-6","volume":"24","author":"R Jalang\u2019o","year":"2025","unstructured":"Jalang\u2019o, R. et al. Subnational introduction of the RTS,S\/AS01(E) malaria vaccine into routine immunization: experience and lessons from the three pilot countries. Malar. J. 24, 244 https:\/\/doi.org\/10.1186\/s12936-025-05484-6 (2025).","journal-title":"Malar. J."},{"key":"1607_CR55","doi-asserted-by":"publisher","unstructured":"McNeil, S. A. et al. Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers. Clin. Infect. Dis. 41, 1114\u20131122 https:\/\/doi.org\/10.1086\/444458 (2005).","DOI":"10.1086\/444458"},{"key":"1607_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126205","volume":"42","author":"MB Finn","year":"2024","unstructured":"Finn, M. B. et al. Immunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine. Vaccine 42, 126205 https:\/\/doi.org\/10.1016\/j.vaccine.2024.126205 (2024).","journal-title":"Vaccine"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01607-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01607-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01607-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T20:02:11Z","timestamp":1791748931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01607-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,11]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1607"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01607-5","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,11]]},"assertion":[{"value":"28 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"189"}}